Focal segmental glomerulosclerosis pathophysiology: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Line 16: Line 16:
The pathogenesis of Primary or Idiopathic FSGS is not so clear. Many studies had theorized that FSGS occurs as a consequence of effects of circulating immune activating factors on the glomerular epithelium. Indeed, the damaging role of circulating factors like the soluble urokinase plasminogen activating receptor (suPAR) on the glomerular podocytes had been postulated.<ref name="pmidPMID 25168830">{{cite journal| author=Reiser J, Nast CC, Alachkar N| title=Permeability factors in focal and segmental glomerulosclerosis. | journal=Adv Chronic Kidney Dis | year= 2014 | volume= 21 | issue= 5 | pages= 417-21 | pmid=PMID 25168830 | doi=10.1053/j.ackd.2014.05.010 | pmc=4149759 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25168830  }} </ref> However, there are not enough clinical data to support this pathogenic theory probably because of the several other physiologic forms of suPAR that can be identified by ELIZA.<ref name="pmid23138488">{{cite journal| author=Wei C, Trachtman H, Li J, Dong C, Friedman AL, Gassman JJ et al.| title=Circulating suPAR in two cohorts of primary FSGS. | journal=J Am Soc Nephrol | year= 2012 | volume= 23 | issue= 12 | pages= 2051-9 | pmid=23138488 | doi=10.1681/ASN.2012030302 | pmc=3507361 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23138488  }} </ref>  
The pathogenesis of Primary or Idiopathic FSGS is not so clear. Many studies had theorized that FSGS occurs as a consequence of effects of circulating immune activating factors on the glomerular epithelium. Indeed, the damaging role of circulating factors like the soluble urokinase plasminogen activating receptor (suPAR) on the glomerular podocytes had been postulated.<ref name="pmidPMID 25168830">{{cite journal| author=Reiser J, Nast CC, Alachkar N| title=Permeability factors in focal and segmental glomerulosclerosis. | journal=Adv Chronic Kidney Dis | year= 2014 | volume= 21 | issue= 5 | pages= 417-21 | pmid=PMID 25168830 | doi=10.1053/j.ackd.2014.05.010 | pmc=4149759 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25168830  }} </ref> However, there are not enough clinical data to support this pathogenic theory probably because of the several other physiologic forms of suPAR that can be identified by ELIZA.<ref name="pmid23138488">{{cite journal| author=Wei C, Trachtman H, Li J, Dong C, Friedman AL, Gassman JJ et al.| title=Circulating suPAR in two cohorts of primary FSGS. | journal=J Am Soc Nephrol | year= 2012 | volume= 23 | issue= 12 | pages= 2051-9 | pmid=23138488 | doi=10.1681/ASN.2012030302 | pmc=3507361 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23138488  }} </ref>  
===Role of "Circulating Permeability Factor"===
===Role of "Circulating Permeability Factor"===
The initial insult that causes effacement of foot processes is yet to be discovered. Circulating factors implicated in the pathogenesis of Primary FSGS include the Soluble Urokinase Plasminogen Activating Receptor (suPAR)and MicroRNAs. MicroRNAs  are small endogenous (18 to 24 nucleotides long) noncoding single-stranded RNAs that regulate gene expression at the post-transcriptional level. Specifically, microRNAs bind to the messenger RNAs of various genes and lead to their breakdown. <ref name="pmidPMID 25168830">{{cite journal| author=Reiser J, Nast CC, Alachkar N| title=Permeability factors in focal and segmental glomerulosclerosis. | journal=Adv Chronic Kidney Dis | year= 2014 | volume= 21 | issue= 5 | pages= 417-21 | pmid=PMID 25168830 | doi=10.1053/j.ackd.2014.05.010 | pmc=4149759 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25168830  }} </ref>Expression of a specific microRNA called miR-193a produced FSGS in mice but its implication in human podocytopathy has not been clearly defined. Nonetheless, Shalhoub and colleagues hypothesized in 1974 the involvement of "circulating permeability factor".<ref name="pmid4140273">{{cite journal| author=Shalhoub RJ| title=Pathogenesis of lipoid nephrosis: a disorder of T-cell function. | journal=Lancet | year= 1974 | volume= 2 | issue= 7880 | pages= 556-60 | pmid=4140273 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=4140273  }} </ref> In fact, several elements favor the pathological role of "circulating permeability factor" in FSGS:
The initial insult that causes effacement of foot processes is yet to be discovered. Circulating factors implicated in the pathogenesis of Primary FSGS include the Soluble Urokinase Plasminogen Activating Receptor (suPAR)and MicroRNAs. MicroRNAs  are small endogenous (18 to 24 nucleotides long) noncoding single-stranded RNAs that regulate gene expression at the post-transcriptional level. Specifically, microRNAs bind to the messenger RNAs of various genes and lead to their breakdown. <ref name="pmidPMID 25168830">{{cite journal| author=Reiser J, Nast CC, Alachkar N| title=Permeability factors in focal and segmental glomerulosclerosis. | journal=Adv Chronic Kidney Dis | year= 2014 | volume= 21 | issue= 5 | pages= 417-21 | pmid=PMID 25168830 | doi=10.1053/j.ackd.2014.05.010 | pmc=4149759 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25168830  }} </ref>Expression of a specific microRNA called miR-193a produced FSGS in mice but its implication in human podocytopathy has not been clearly defined.  
suPAR is a heavily glycosylated protein that can be found in several places. It can be present as different fragments and also with various degrees of glycosylation. Both fragmentation and glycosylation of suPAR determine its function and the way it is measured (mainly by ELISA). The most pathogenic form of suPAR for podocytes is still not well defined but there are laboratory evidences of suPAR causing FSGS in lab mice <ref name="pmid23138488">{{cite journal| author=Wei C, Trachtman H, Li J, Dong C, Friedman AL, Gassman JJ et al.| title=Circulating suPAR in two cohorts of primary FSGS. | journal=J Am Soc Nephrol | year= 2012 | volume= 23 | issue= 12 | pages= 2051-9 | pmid=23138488 | doi=10.1681/ASN.2012030302 | pmc=3507361 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23138488  }} </ref> and several cohort studies linking high level of suPAR to FSGS.<ref name="pmid23447064">{{cite journal| author=Huang J, Liu G, Zhang YM, Cui Z, Wang F, Liu XJ et al.| title=Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis. | journal=Kidney Int | year= 2013 | volume= 84 | issue= 2 | pages= 366-72 | pmid=23447064 | doi=10.1038/ki.2013.55 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23447064  }} </ref>
Nonetheless, Shalhoub and colleagues hypothesized in 1974 the involvement of "circulating permeability factor".<ref name="pmid4140273">{{cite journal| author=Shalhoub RJ| title=Pathogenesis of lipoid nephrosis: a disorder of T-cell function. | journal=Lancet | year= 1974 | volume= 2 | issue= 7880 | pages= 556-60 | pmid=4140273 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=4140273  }} </ref> In fact, several elements favor the pathological role of "circulating permeability factor" in FSGS:
*Recurrence of proteinuria following renal transplantation<ref name="pmid1994534">{{cite journal| author=Ingulli E, Tejani A| title=Incidence, treatment, and outcome of recurrent focal segmental glomerulosclerosis posttransplantation in 42 allografts in children--a single-center experience. | journal=Transplantation | year= 1991 | volume= 51 | issue= 2 | pages= 401-5 | pmid=1994534 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1994534  }} </ref>
*Recurrence of proteinuria following renal transplantation<ref name="pmid1994534">{{cite journal| author=Ingulli E, Tejani A| title=Incidence, treatment, and outcome of recurrent focal segmental glomerulosclerosis posttransplantation in 42 allografts in children--a single-center experience. | journal=Transplantation | year= 1991 | volume= 51 | issue= 2 | pages= 401-5 | pmid=1994534 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1994534  }} </ref>


Revision as of 15:41, 20 October 2016

Focal segmental glomerulosclerosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Focal segmental glomerulosclerosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X-Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Focal segmental glomerulosclerosis pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Focal segmental glomerulosclerosis pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Focal segmental glomerulosclerosis pathophysiology

CDC on Focal segmental glomerulosclerosis pathophysiology

Focal segmental glomerulosclerosis pathophysiology in the news

Blogs on Focal segmental glomerulosclerosis pathophysiology

Directions to Hospitals Treating Focal segmental glomerulosclerosis

Risk calculators and risk factors for Focal segmental glomerulosclerosis pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Ali Poyan Mehr, M.D. [2]; Associate Editor-In-Chief:’’’ Cafer Zorkun, M.D., Ph.D. [3]; Olufunmilola Olubukola M.D.[4]

Overview

Pathophysiology

The underlying pathogenesis of FSGS clinical signs and symptoms is fusion or effacement of the foot processes (podocytes) of the glomeruli, with sclerosing of some part of the glomeruli (hence its name as focal segmental). FSGS is believed to a histological variant of Minimal Change Kidney Disease rather than a clinical disease by itself. The clinical hallmark of focal segmental glomerulosclerosis (FSGS) is proteinuria and nephrotic syndrome. As such, the involvement of the permselective filtration barrier and effacement of podocyte foot processes are inevitable.[1] According to Asanuma and colleagues[1], 4 major causes that lead to the reaction of podocyte foot processes. These changes result in apoptosis, detachment from the glomerular basement membrane (GBM), and subsequent podocytopenia[2]:

  1. Interference with slit diaphragm and its corresponding lipid raft
  2. Interference with actin cytoskeleton
  3. Interference with the GBM or with the interaction of the GBM and the podocytes
  4. Interference with the negative charge of podocytes

The pathogenesis of Primary or Idiopathic FSGS is not so clear. Many studies had theorized that FSGS occurs as a consequence of effects of circulating immune activating factors on the glomerular epithelium. Indeed, the damaging role of circulating factors like the soluble urokinase plasminogen activating receptor (suPAR) on the glomerular podocytes had been postulated.[3] However, there are not enough clinical data to support this pathogenic theory probably because of the several other physiologic forms of suPAR that can be identified by ELIZA.[4]

Role of "Circulating Permeability Factor"

The initial insult that causes effacement of foot processes is yet to be discovered. Circulating factors implicated in the pathogenesis of Primary FSGS include the Soluble Urokinase Plasminogen Activating Receptor (suPAR)and MicroRNAs. MicroRNAs are small endogenous (18 to 24 nucleotides long) noncoding single-stranded RNAs that regulate gene expression at the post-transcriptional level. Specifically, microRNAs bind to the messenger RNAs of various genes and lead to their breakdown. [3]Expression of a specific microRNA called miR-193a produced FSGS in mice but its implication in human podocytopathy has not been clearly defined. suPAR is a heavily glycosylated protein that can be found in several places. It can be present as different fragments and also with various degrees of glycosylation. Both fragmentation and glycosylation of suPAR determine its function and the way it is measured (mainly by ELISA). The most pathogenic form of suPAR for podocytes is still not well defined but there are laboratory evidences of suPAR causing FSGS in lab mice [4] and several cohort studies linking high level of suPAR to FSGS.[5] Nonetheless, Shalhoub and colleagues hypothesized in 1974 the involvement of "circulating permeability factor".[6] In fact, several elements favor the pathological role of "circulating permeability factor" in FSGS:

  • Recurrence of proteinuria following renal transplantation[7]
  • Absence of proteinuria in patients following transplantation in recipients of kidneys from donors with FSGS[8]
  • Effectiveness of extracorporeal plasmapheresis in decreasing the degree of proteinuria[9]
  • In vitro studies showing permeability alterations by FSGS serum on isolated glomeruli[10]
  • Transmissibility of glomerular permeability factor from the mother to her infant during gestation[11]

Role of Proteinuria

Proteinuria, an important predictor of prognosis, further exacerbates renal disease by inducing tubulointerstitial injury. Proteinuria induces the activation of immune cells, such as macrophages and T-cells, and cytokines, such as tumor growth factor-beta (TGF-beta), interleukin (IL) 1, and tumor necrosis factor-alpha (TNF-alpha).[12]

Role of Inflammatory Mediators

The progression of FSGS is highly dependent on the presence of pro-inflammatory cytokines and vasoactive factors that also play a major role in renal fibrosis. Overexpression of tumor growth factor-beta (TGF-beta), platelet-derived growth factor (PDGF), and vascular endothelial growth factor (VEGF) contributes to the progression of disease and is associated with the extent of glomerulosclerosis.[13][14] Activated cytokines promote cellular infiltration and desposition of collagen along the mesangial matrix.[14]

Maladaptive Interactions

Following the loss of podocytes, maladaptive interactions occur between the GBM and the renal epithelial cells, leading to proliferation of epithelial, endothelial, and mesangial cells.[2] The resultant collagen deposition then contributes to the scarring of the glomerular tufts that appear as focal and segmental regions of glomerulosclerosis as seen on pathology. The diseased regions then progress to involve larger areas of the kidneys and eventually become diffusely sclerotic, causing end-stage renal disease (ESRD).[2]

Role of Mechanical Stresses

Defects of the glomerular filtration barrier leads to an overwhelmingly increased single nephron glomerular filtration rate (SNGFR). This mechanical stress helps in the progression of FSGS by creating a state of hypertrophy that worsens the lack of balance between the GBM and the podocytopenia, and thus worsens the extent of injury.[15][16]

Role of Genetics

There are currently several mutations in cytoskeletal and membrane proteins that lead to familial FSGS:

  • Nephrin gene in congenital Finnish-type nephrotic syndrome - NPHS1[17][15]
  • Nephrin-like transmembrane gene - NEPH1[1]
  • Podocin gene - NPHS2[18]
  • CD2-associated protein (CD2AP)[19][20]
  • Alpha-actinin-4 gene [21]
  • Transient receptor potential cation channel - TRPC6[22]
  • Mutation in wilms tumor gene - WT1[23]
  • Mutation in SCARB2 (LIMP2) gene[23]
  • Mutation in formin gene - INF2[23]
  • Mitochondrial cytopathies[23]

References

  1. ↑ 1.0 1.1 1.2 Asanuma K, Mundel P (2003). "The role of podocytes in glomerular pathobiology". Clin Exp Nephrol. 7 (4): 255–9. doi:10.1007/s10157-003-0259-6. PMID 14712353.
  2. ↑ 2.0 2.1 2.2 Fogo AB (2003). "Animal models of FSGS: lessons for pathogenesis and treatment". Semin Nephrol. 23 (2): 161–71. doi:10.1053/snep.2003.50015. PMID 12704576.
  3. ↑ 3.0 3.1 Reiser J, Nast CC, Alachkar N (2014). "Permeability factors in focal and segmental glomerulosclerosis". Adv Chronic Kidney Dis. 21 (5): 417–21. doi:10.1053/j.ackd.2014.05.010. PMC 4149759. PMID 25168830 PMID 25168830 Check |pmid= value (help).
  4. ↑ 4.0 4.1 Wei C, Trachtman H, Li J, Dong C, Friedman AL, Gassman JJ; et al. (2012). "Circulating suPAR in two cohorts of primary FSGS". J Am Soc Nephrol. 23 (12): 2051–9. doi:10.1681/ASN.2012030302. PMC 3507361. PMID 23138488.
  5. ↑ Huang J, Liu G, Zhang YM, Cui Z, Wang F, Liu XJ; et al. (2013). "Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis". Kidney Int. 84 (2): 366–72. doi:10.1038/ki.2013.55. PMID 23447064.
  6. ↑ Shalhoub RJ (1974). "Pathogenesis of lipoid nephrosis: a disorder of T-cell function". Lancet. 2 (7880): 556–60. PMID 4140273.
  7. ↑ Ingulli E, Tejani A (1991). "Incidence, treatment, and outcome of recurrent focal segmental glomerulosclerosis posttransplantation in 42 allografts in children--a single-center experience". Transplantation. 51 (2): 401–5. PMID 1994534.
  8. ↑ Rea R, Smith C, Sandhu K, Kwan J, Tomson C (2001). "Successful transplant of a kidney with focal segmental glomerulosclerosis". Nephrol Dial Transplant. 16 (2): 416–7. PMID 11158426.
  9. ↑ Ghiggeri GM, Artero M, Carraro M, Perfumo F (2001). "Permeability plasma factors in nephrotic syndrome: more than one factor, more than one inhibitor". Nephrol Dial Transplant. 16 (5): 882–5. PMID 11328888.
  10. ↑ Savin VJ, McCarthy ET, Sharma M (2003). "Permeability factors in focal segmental glomerulosclerosis". Semin Nephrol. 23 (2): 147–60. doi:10.1053/snep.2003.50024. PMID 12704575.
  11. ↑ Kemper MJ, Wolf G, Müller-Wiefel DE (2001). "Transmission of glomerular permeability factor from a mother to her child". N Engl J Med. 344 (5): 386–7. doi:10.1056/NEJM200102013440517. PMID 11195803.
  12. ↑ Walls J (2001). "Relationship between proteinuria and progressive renal disease". Am J Kidney Dis. 37 (1 Suppl 2): S13–6. PMID 11158854.
  13. ↑ Kang DH, Joly AH, Oh SW, Hugo C, Kerjaschki D, Gordon KL; et al. (2001). "Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1". J Am Soc Nephrol. 12 (7): 1434–47. PMID 11423572.
  14. ↑ 14.0 14.1 Harris RC, Neilson EG (2006). "Toward a unified theory of renal progression". Annu Rev Med. 57: 365–80. doi:10.1146/annurev.med.57.121304.131342. PMID 16409155.
  15. ↑ 15.0 15.1 Kwoh C, Shannon MB, Miner JH, Shaw A (2006). "Pathogenesis of nonimmune glomerulopathies". Annu Rev Pathol. 1: 349–74. doi:10.1146/annurev.pathol.1.110304.100119. PMID 18039119.
  16. ↑ Hostetter TH (2003). "Hyperfiltration and glomerulosclerosis". Semin Nephrol. 23 (2): 194–9. doi:10.1053/anep.2003.50017. PMID 12704579.
  17. ↑ Kestilä M, Lenkkeri U, Männikkö M, Lamerdin J, McCready P, Putaala H; et al. (1998). "Positionally cloned gene for a novel glomerular protein--nephrin--is mutated in congenital nephrotic syndrome". Mol Cell. 1 (4): 575–82. PMID 9660941.
  18. ↑ Tryggvason K, Patrakka J, Wartiovaara J (2006). "Hereditary proteinuria syndromes and mechanisms of proteinuria". N Engl J Med. 354 (13): 1387–401. doi:10.1056/NEJMra052131. PMID 16571882.
  19. ↑ Shih NY, Li J, Karpitskii V, Nguyen A, Dustin ML, Kanagawa O; et al. (1999). "Congenital nephrotic syndrome in mice lacking CD2-associated protein". Science. 286 (5438): 312–5. PMID 10514378.
  20. ↑ Kim JM, Wu H, Green G, Winkler CA, Kopp JB, Miner JH; et al. (2003). "CD2-associated protein haploinsufficiency is linked to glomerular disease susceptibility". Science. 300 (5623): 1298–300. doi:10.1126/science.1081068. PMID 12764198.
  21. ↑ Kaplan JM, Kim SH, North KN, Rennke H, Correia LA, Tong HQ; et al. (2000). "Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis". Nat Genet. 24 (3): 251–6. doi:10.1038/73456. PMID 10700177.
  22. ↑ Winn MP (2003). "Approach to the evaluation of heritable diseases and update on familial focal segmental glomerulosclerosis". Nephrol Dial Transplant. 18 Suppl 6: vi14–20. PMID 12953036.
  23. ↑ 23.0 23.1 23.2 23.3 Beck L, Bomback AS, Choi MJ, Holzman LB, Langford C, Mariani LH; et al. (2013). "KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis". Am J Kidney Dis. 62 (3): 403–41. doi:10.1053/j.ajkd.2013.06.002. PMID 23871408.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Focal_segmental_glomerulosclerosis_pathophysiology&oldid=1262646"